-
公开(公告)号：US20240182401A1
公开(公告)日：2024-06-06
申请号：US18550845
申请日：2022-03-19
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Jayprakash Ajitsingh PARIHAR , Prashant Pandurang PAWAR , Praveen Raosaheb SUPEKAR , Ashutosh Akhilesh RAGHUWANSHI , Vaibhav Vilas TATTE
CPC classification number: C07C51/412 , A61K31/19 , C07B2200/13
Abstract: The present invention provides an improved scalable process for preparation of mixed oxybate salts. More particularly, the present invention provides a process of preparation of a mixture of sodium, potassium, magnesium and calcium oxybate salts. Further, the present invention provides polymorphs of each of the individual salts and the mixed salt along with the methods of preparation of each.
-
公开(公告)号：US20250064827A1
公开(公告)日：2025-02-27
申请号：US18943210
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：US20240173331A1
公开(公告)日：2024-05-30
申请号：US18549916
申请日：2021-06-14
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
CPC classification number: A61K31/55 , A61K9/0043 , A61K45/06 , A61K47/02 , A61K47/183 , A61K47/186 , A61K47/38
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：US20250064828A1
公开(公告)日：2025-02-27
申请号：US18943269
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：US20250064826A1
公开(公告)日：2025-02-27
申请号：US18943165
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
Patent Agency Ranking
公开(公告)号：US20240374527A1
公开(公告)日：2024-11-14
申请号：US18655810
申请日：2024-05-06
Applicant: Alkem Laboratories Limited
Inventor： Madhusudan Hanchate , Vaibhav Magar , Satyanarayana Tallam , Prakash Ramnani , Srinivas Singh , ArunKumar Pandey , Umadoss Pothuvan
IPC: A61K9/48 , A61K31/4985
Abstract: The present invention relates to a pharmaceutical composition for oral administration comprising: a) about 5% w/w to about 40% w/w of lumateperone or pharmaceutically acceptable salt thereof; b) about 50% w/w to about 95% w/w of at least one diluent; c) about 1% w/w to about 10% w/w of at least one disintegrant; d) about 0.1% w/w to about 2% w/w of at least one glidant; and e) about 0.5% w/w to about 5% w/w of a lubricant selected from the group consisting of sodium stearyl fumarate, stearic acid, and combinations thereof, wherein the amount of nitrosamine impurity after exposure of the pharmaceutical composition to 40° C./75% RH for a period of six months is less than the FDA acceptable intake limit of the nitrosamine impurity based on maximum daily dose of lumateperone.
-
公开(公告)号：US20230218630A1
公开(公告)日：2023-07-13
申请号：US17997656
申请日：2021-06-14
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Ulhas DHUPPAD , Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
CPC classification number: A61K31/55 , A61K31/56 , A61K9/0043 , A61K47/183 , A61K47/02 , A61K9/10
Abstract: The present invention relates to a topical pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt thereof and a corticosteroid or a pharmaceutically acceptable salt thereof, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with a combination of alcaftadine or a pharmaceutically acceptable salt thereof and a corticosteroid or a pharmaceutically acceptable salt thereof, and methods of preparing the topical composition.
-
公开(公告)号：US20250064825A1
公开(公告)日：2025-02-27
申请号：US18943124
申请日：2024-11-11
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Akhilesh SHARMA , Babasaheb AWARE , Viraj SHAH , Amol AIWALE
Abstract: The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.
-
公开(公告)号：USD1063062S1
公开(公告)日：2025-02-18
申请号：US29852811
申请日：2022-09-09
Applicant: Alkem Laboratories Limited
-
公开(公告)号：US20230240985A1
公开(公告)日：2023-08-03
申请号：US18160866
申请日：2023-01-27
Applicant: ALKEM LABORATORIES LIMITED
Inventor： Arun Kumar Pandey , Umadoss Pothuvan , Gaurav Chaurasia , Chaitanya Shrisath , Ulhas Dhuppad , Abhay Rahangdale
CPC classification number: A61K9/0053 , A61K9/08 , A61K31/357 , A61K47/10 , A61K47/26 , A61K47/46
Abstract: The present invention relates to a stable pharmaceutical composition of Topiramate and process for the preparation thereof. This invention more particularly relates to a stable aqueous pharmaceutical composition comprising Topiramate and process for the preparation thereof.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.014 seconds)
